ArticleClinical rheumatology2024

Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study.

Po-Cheng Shih et al.PubMed ↗Publisher ↗

No numbers read from the abstract.